Shock Syndromes II

Hypovolemic Shock

Alvarado R, Chung KK, Cancio LC, Wolf SE. Burn

resuscitation.

Burns.

2009;35(1):4-14. https://doi.

org/10.1016/j.burns.2008.03.008

American College of Surgeons. Committee on Trauma:

Advanced Trauma Life Support Manual. American

College of Surgeons; 1997:103-112.

Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et

al. Platelet transfusion versus standard care after acute

stroke due to spontaneous cerebral haemorrhage associ-

ated with antiplatelet therapy (PATCH): a randomised,

2613. https://doi.org/10.1016/s0140-6736(16)30392-0

Baksaas-Aasen K, Gall LS, Stensballe J, et al.

Viscoelastic haemostatic assay augmented protocols for

major trauma haemorrhage (ITACTIC): a randomized,

https://doi.org/10.1007/s00134-020-06266-1

Boffard KD, Riou B, Warren B, et al. Recombinant fac-

tor VIIa as adjunctive therapy for bleeding control in

severely injured trauma patients: two parallel random-

ized, placebo-controlled, double-blind clinical trials.

J Trauma. 2005;59(1):8-18. https://doi.org/10.1097/01.

ta.0000171453.37949.b7

Bourke DL, Smith TC. Estimating allowable hemodi-

lution. Anesthesiology. 1974;41(6):609-612. https://doi.

org/10.1097/00000542-197412000-00015

Bouzat P, Charbit J, Abback PS, et al. Efficacy and safety

of early administration of 4-factor prothrombin complex

concentrate in patients with trauma at risk of massive

transfusion: the PROCOAG randomized clinical trial.

jama.2023.4080

Brohi K, Singh J, Heron M, Coats T. Acute traumatic

coagulopathy. J Trauma. 2003;54(6):1127-1130. https://

doi.org/10.1097/01.ta.0000069184.82147.06

Cannon JW. Hemorrhagic shock. N Engl J Med.

2018;378(4):370-379.

https://doi.org/10.1056/

nejmra1705649

Cannon JW, Khan MA, Raja AS, et al. Damage control

resuscitation in patients with severe traumatic hemor-

rhage: a practice management guideline from the Eastern

Association for the Surgery of Trauma. J Trauma Acute

Care Surg. 2017;82(3):605-617. https://doi.org/10.1097/

ta.0000000000001333

Carney N, Totten AM, O’Reilly C, et al. Guidelines for

the management of severe traumatic brain injury, fourth

edition. Neurosurgery. 2017;80(1):6-15. https://doi.

org/10.1227/NEU.0000000000001432

Connolly SJ, Crowther M, Eikelboom JW, et al. Full study

report of andexanet alfa for bleeding associated with

factor Xa inhibitors. N Engl J Med. 2019;380(14):1326-

1335. https://doi.org/10.1056/nejmoa1814051

Connolly SJ, Sharma M, Cohen AT, et al. Andexanet for

factor Xa inhibitor-associated acute intracerebral hem-

orrhage. N Engl J Med. 2024;390(19):1745-1755. https://

doi.org/10.1056/nejmoa2313040

CRASH-2 Trial Collaborators; Shakur H, Roberts

I, Bautista R, et al. Effects of tranexamic acid on

death, vascular occlusive events, and blood transfu-

sion in trauma patients with significant haemorrhage

(CRASH-2): a randomised, placebo-controlled trial.

s0140-6736(10)60835-5

CRASH-3 Trial Collaborators. Effects of tranexamic

acid on death, disability, vascular occlusive events and

other morbidities in patients with acute traumatic brain

injury (CRASH-3): a randomised, placebo-controlled

org/10.1016/s0140-6736(19)32233-0

Dager WE. Developing a management plan for oral anti-

suppl 1):S21-S31. https://doi.org/10.2146/ajhp130042

De Backer D, Biston P, Devriendt J, et al. Comparison

of dopamine and norepinephrine in the treatment of

shock. N Engl J Med. 2010;362(9):779-789. https://doi.

org/10.1056/nejmoa0907118

Delano MJ, Rizoli SB, Rhind SG, et al. Prehospital resus-

citation of traumatic hemorrhagic shock with hypertonic

solutions worsens hypocoagulation and hyperfibrinoly-

sis. Shock. 2015;44(1):25-31. https://doi.org/10.1097/

shk.0000000000000368

Eriksson BI, Quinlan DJ, Weitz JI. Comparative phar-

macodynamics and pharmacokinetics of oral direct

thrombin and factor Xa inhibitors in development.

Clin

Pharmacokinet.

2009;48(1):1-22.

https://doi.

org/10.2165/0003088-200948010-00001